title: Urodynamic effects of silodosin, a new alpha 1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia.
abstract: OBJECTIVE
  To investigate urodynamically the effects of silodosin, a new alpha(1A)-adrenoceptor-selective antagonist, in the treatment of benign prostatic hyperplasia (BPH).
  
  
  METHODS
  Thirty six male patients with BPH (69.9 +/- 7.3 years), who were referred as candidates for surgery, were treated with silodosin (4 mg twice daily). The total International Prostate Symptom Score (IPSS) was 20.7 +/- 7.4, maximum flow rate (Q(max)) was 6.7 +/- 3.0 ml/sec, and prostate volume was 45.6 +/- 24.5 ml.
  
  
  RESULTS
  Total IPSS, storage and voiding symptom subscores and QOL score decreased significantly, and Q(max) increased significantly after 1-12 months of therapy (all P < 0.05). In urodynamic study (n = 29), maximum cystometric capacity increased significantly (P = 0.0027), and detrusor overactivity disappeared in 8 of 20 patients (40%) and improved (bladder capacity increased more than 50%) in 7 (35%) after the therapy. In pressure/flow studies (n = 27), the obstruction grade was improved in 15 patients (56%). Detrusor opening pressure, detrusor pressure at Q(max), bladder outlet obstruction index, and Schäfer's obstruction class decreased significantly after therapy (all P < 0.01). After 12 months, 16 patients (44%) are still on silodosin for 23.3 +/- 7.0 (range 12-36) months, and the improvements in IPSS and Q(max) were stable. Twenty patients withdrew because of insufficient effectiveness in 13 patients (12 patients underwent surgery), side effects in 3, and unknown reasons in 4.
  
  
  CONCLUSIONS
  Silodosin appears to improve detrusor overactivity and obstruction grade in patients with BPH. With silodosin treatment, LUTS could be managed effectively for more than a year in at least 44% of the patients.
authors.affiliation: Department of Urology, Dokkyo Medical University, Tochigi, Japan. yamanish@dokkyomed.ac.jp
authors.forename: Tomonori
authors.initials: T
authors.lastname: Yamanishi
authors.forename: Tomoya
authors.initials: T
authors.lastname: Mizuno
authors.forename: Katsuhisa
authors.initials: K
authors.lastname: Tatsumiya
authors.forename: Miho
authors.initials: M
authors.lastname: Watanabe
authors.forename: Takao
authors.initials: T
authors.lastname: Kamai
authors.forename: Ken-Ichiro
authors.initials: K
authors.lastname: Yoshida
mesh_terms: D058668:Adrenergic alpha-1 Receptor Antagonists; D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D018340:Receptors, Adrenergic, alpha-1; D012720:Severity of Illness Index; D016896:Treatment Outcome; D001748:Urinary Bladder Neck Obstruction / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D014563:Urodynamics
chemical_list: C547713:ADRA1A protein, human; D058668:Adrenergic alpha-1 Receptor Antagonists; D007211:Indoles; D018340:Receptors, Adrenergic, alpha-1; C095285:silodosin